Cardiac glycosides stimulate phospholipase C activity in rat pinealocytes.
Ouabain and related cardiac glycosides stimulate phospholipase C activity 5-fold in rat pinealocytes. The combined treatment of ouabain and norepinephrine, which also stimulates phospholipase C, produces an additive effect. The effects of either ouabain or norepinephrine are blocked by EGTA. However, there are notable differences. The stimulatory effect of ouabain is lost when extracellular Na+ is reduced to 20 mM and is not blocked by prazosin. In contrast, the stimulatory effect of norepinephrine is not blocked when extracellular Na+ is reduced to 20 mM but is blocked by prazosin. Ouabain appears to increase phospholipase C activity through a mechanism involving inhibition of Na+,K+-ATPase, and an accumulation of intracellular Na+ and Ca2+, not involving alpha 1-adrenoceptors. These findings raise the possibility that activation of phospholipase C might be a more general effect of cardiac glycosides.
D000818:Animals; D002118:Calcium / Q000502:physiology; D004533:Egtazic Acid / Q000494:pharmacology; D005260:Female; D009638:Norepinephrine / Q000494:pharmacology; D010042:Ouabain / Q000494:pharmacology*; D010870:Pineal Gland / Q000187:drug effects / Q000201:enzymology*; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011942:Receptors, Adrenergic, alpha / Q000502:physiology; D012964:Sodium / Q000502:physiology; D010738:Type C Phospholipases / Q000378:metabolism*
D011942:Receptors, Adrenergic, alpha; D004533:Egtazic Acid; D010042:Ouabain; D012964:Sodium; D010738:Type C Phospholipases; D002118:Calcium; D009638:Norepinephrine; D011224:Prazosin